Pharmaceutical composition for improving or treating autosomal dominant polycystic kidney disease comprising dna methylation inhibitor
A methylation inhibitor, autosomal technology, used in gene therapy, carbohydrate active ingredients, chemical instruments and methods, etc., can solve the problems of lack of analysis, negative feedback obstacles, disappointing clinical results, etc.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment Construction
[0077] The present invention provides a pharmaceutical composition for improvement or treatment of autosomal dominant polycystic kidney containing DNA methylation inhibitor.
[0078] The above-mentioned DNA methylation inhibitor is not particularly limited but is expected to be characterized by 5-aza-dC (5-aza-2'-deoxycytidine) or zebularine.
[0079] The composition of the present invention is one or more polycystic kidney treatment agents or used together with improving agents.
[0080] The composition of the present invention contains the above-mentioned active ingredients suitable for pharmacological and physiologically approved auxiliary agents, these auxiliary agents include excipients, disintegrants, sweeteners, binding agents, coating agents, bulking agents, lubricants, Slip modifiers or solubilizers, etc.
[0081] In addition, the composition of the present invention adds one or more pharmacologically permitted carriers in addition to the above-mentioned effective ingredients...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com